GLP-1 agonists, DPP-4 inhibitors off the hook, for now
This article was originally published in Scrip
Executive Summary
There is currently no evidence that GLP-1 agonists and DPP-4 inhibitors lead to a heightened risk of pancreatic adverse events, says the European Medicines Agency's Committee for Medicinal Products for Human Use. The CHMP has recently concluded a review of the products and found that a study that sparked concerns was limited in several ways.